Table 3.
Comparison of PHQ-9 and SF-12v2 component scores by detection status in the PHQ-9 positive cohort
| Doctor detection (−ve) | Doctor detection (+ve) | P value | |
|---|---|---|---|
| Raw scores at each time point | |||
| PHQ-9 score (mean ± SD) | |||
| At baseline | 13.3±3.2 | 14.9±4.1 | <0.001* |
| At 12 weeks | 6.4±4.5 | 8.1±5.5 | 0.007* |
| At 26 weeks | 5.8±4.6 | 7.3±6.3 | 0.029* |
| At 52 weeks | 5.2±4.8 | 6.1±5.6 | 0.113 |
| SF-12v2 PCS (mean ± SD) | |||
| At baseline | 42.8±11.8 | 41.9±12.2 | 0.500 |
| At 12 weeks | 43.2±12.2 | 42.0±12.4 | 0.505 |
| At 26 weeks | 46.4±10.8 | 45.5±11.1 | 0.559 |
| At 52 weeks | 47.6±10.2 | 45.8±11.9 | 0.139 |
| SF-12v2 MCS (mean ± SD) | |||
| At baseline | 40.0±11.8 | 31.8±12.3 | <0.001* |
| At 12 weeks | 48.0±10.6 | 45.5±12.3 | 0.093 |
| At 26 weeks | 49.3±11.3 | 46.9±14.0 | 0.156 |
| At 52 weeks | 50.8±11.0 | 49.5±11.9 | 0.325 |
| Difference in scores between baseline and each subsequent follow-up time point | |||
| PHQ-9 score (mean ± SD) | |||
| Between baseline and 12 weeks | −7.0±5.0 | −7.2±6.3 | 0.785 |
| Between baseline and 26 weeks | −7.3±4.6 | −7.4±7.1 | 0.894 |
| Between baseline and 52 weeks | −8.1±5.5 | −8.8±6.6 | 0.313 |
| SF-12v2 PCS (mean ± SD) | |||
| Between baseline and 12 weeks | 0.8±12.2 | 0.6±12.8 | 0.904 |
| Between baseline and 26 weeks | 3.3±11.2 | 4.4±13.7 | 0.501 |
| Between baseline and 52 weeks | 5.3±11.1 | 3.8±12.8 | 0.270 |
| SF-12v2 MCS (mean ± SD) | |||
| Between baseline and 12 weeks | 6.9±12.2 | 14.7±13.5 | <0.001* |
| Between baseline and 26 weeks | 10.0±13.2 | 15.3±14.5 | 0.005* |
| Between baseline and 52 weeks | 10.7±13.4 | 16.8±14.7 | <0.001* |
*Significant difference (P < 0.05) between groups by independent t-test.